2022. Novel substituted 5-arylidene-1, 3-thiazolidin-4-one analogues: Synthesis, optimization, anticancer screening and docking studies. Journal of Pharmaceutical Negative Results. (Oct. 2022), 2378–2389. DOI:https://doi.org/10.47750/pnr.2022.13.S06.310.